Literature DB >> 17162223

Hepatic fibrosis, stellate cells, and portal hypertension.

Don C Rockey1.   

Abstract

Hepatic fibrogenesis is the common result of injury to the liver. It is believed to be a critical factor that leads to hepatic dysfunction and may be important in portal hypertension. The fibrogenic response is a complex process in which accumulation of extracellular matrix proteins, tissue contraction, and alteration in blood flow are prominent. A critical event in fibrogenesis is activation of resident perisinusoidal cells that are termed "hepatic stellate cells". Stellate cell activation is characterized by many important phenotypes, including enhanced extracellular matrix synthesis and prominent contractility. Given the central role of stellate cell activation in hepatic fibrogenesis (and portal hypertension), effective therapy for hepatic fibrogenesis is most likely will be directed at this event.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17162223     DOI: 10.1016/j.cld.2006.08.017

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  38 in total

1.  Preproendothelin-1 expression is negatively regulated by IFNγ during hepatic stellate cell activation.

Authors:  Tianxia Li; Zengdun Shi; Don C Rockey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-02       Impact factor: 4.052

2.  Suppression of hedgehog signaling regulates hepatic stellate cell activation and collagen secretion.

Authors:  Tao Li; Xi-Sheng Leng; Ji-Ye Zhu; Gang Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Probiotics promote rapid-turnover protein production by restoring gut flora in patients with alcoholic liver cirrhosis.

Authors:  Hironori Koga; Yoshitaka Tamiya; Keiichi Mitsuyama; Masahiko Ishibashi; Satoshi Matsumoto; Akemi Imaoka; Taeko Hara; Masatoshi Nakano; Kazutoshi Ooeda; Yoshinori Umezaki; Michio Sata
Journal:  Hepatol Int       Date:  2012-11-21       Impact factor: 6.047

4.  Serum transforming growth factor beta 3 predicts future development of nonalcoholic fatty liver disease.

Authors:  Yongli Wei; Qing Tian; Xiuxia Zhao; Xingchun Wang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 5.  Current concepts on the role of nitric oxide in portal hypertension.

Authors:  Liang Shuo Hu; Jacob George; Jian Hua Wang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

6.  The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis--a multiparametric approach.

Authors:  Diana Feier; Csilla Balassy; Nina Bastati; Romana Fragner; Friedrich Wrba; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2015-05-21       Impact factor: 5.315

7.  Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging.

Authors:  Yi Wang; Daniel R Ganger; Josh Levitsky; Laura A Sternick; Robert J McCarthy; Zongming E Chen; Charles W Fasanati; Bradley Bolster; Saurabh Shah; Sven Zuehlsdorff; Reed A Omary; Richard L Ehman; Frank H Miller
Journal:  AJR Am J Roentgenol       Date:  2011-03       Impact factor: 3.959

8.  Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis.

Authors:  Jian Liang; Xin Deng; Zhi-Xiu Lin; Li-Chun Zhao; Xi-Liu Zhang
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

Review 9.  Stellate cell contraction: role, regulation, and potential therapeutic target.

Authors:  Russell K Soon; Hal F Yee
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

10.  Experimental obstructive cholestasis: the wound-like inflammatory liver response.

Authors:  María-Angeles Aller; Jorge-Luis Arias; Jose García-Domínguez; Jose-Ignacio Arias; Manuel Durán; Jaime Arias
Journal:  Fibrogenesis Tissue Repair       Date:  2008-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.